首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >Comparative analysis of arterial spin labeling and dynamic susceptibility contrast perfusion imaging for quantitative perfusion measurements of brain tumors
【2h】

Comparative analysis of arterial spin labeling and dynamic susceptibility contrast perfusion imaging for quantitative perfusion measurements of brain tumors

机译:动脉自旋标记和动态磁化率对比灌注成像用于脑肿瘤定量灌注测量的对比分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We comparatively analyzed the difference between three-dimensional arterial spin labeling (3D-ASL) and the conventional dynamic susceptibility contrast (DSC) perfusion imaging in the setting of assessing brain tumor perfusion in 28 patients with proved brain tumors. All patients were scheduled with standard MRI, 3D-ASL and DSC scannings on a GE DISCOVERY MR 750 system. Maximal relative tumor perfusion was obtained based on the region of interest (ROI) method. A close correlation between 3D-ASL and DSC perfusion imaging was noted as manifested by the absence of significant differences between ASL nTBF and DSC nTBF when normalized to M (mirror region) and GM (contralateral gray matter). However, ASL nTBF was found to be highly correlated with DSC nTBF and DSC nTBV when normalized to M, GM and WM (contralateral normal white matter). Together, our data support that 3D-ASL possesses the potential to be a noninvasive alternate for DSC-MRI in assessing brain tumor perfusion in the setting of treatment prognosis and metastasis, particularly for those patients with renal failure and patients required for collection of follow up information.
机译:我们比较了三维动脉旋转标记(3D-ASL)与常规动态磁化率对比(DSC)灌注成像之间的差异,以评估28例脑肿瘤患者的脑肿瘤灌注情况。所有患者均计划在GE DISCOVERY MR 750系统上进行标准MRI,3D-ASL和DSC扫描。基于目标区域(ROI)方法获得了最大的相对肿瘤灌注。注意到3D-ASL与DSC灌注成像之间的密切相关性表现为:将ASL nTBF和DSC nTBF标准化为M(镜面区域)和GM(对侧灰质)后,没有显着差异。但是,当将ASL nTBF标准化为M,GM和WM(对侧正常白质)时,发现它们与DSC nTBF和DSC nTBV高度相关。总之,我们的数据支持3D-ASL在评估预后和转移情况下评估脑肿瘤灌注方面,有可能成为DSC-MRI的无创替代药物,特别是对于那些肾衰患者和需要随访的患者信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号